HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bach, L. A. Search for Related Content PubMed PubMed Citation Articles by Bach, L. A. Related Collections Related Article Social Bookmarking                What's this?

Rho Kinase Inhibition: A New Approach for Treating Diabetic Nephropathy?

From the Monash University Department of Medicine and Department of Endocrinology and Diabetes, Alfred Hospital, Melbourne, Victoria, Australia

Address correspondence and reprint requests to Prof. Leon Bach, Department of Endocrinology and Diabetes, Alfred Hospital, Commercial Road, Melbourne, 3004, Victoria, Australia. E-mail: leon.bach@med.monash.edu.au

Abbreviations: AngII, angiotensin II; RAS, renin-angiotensin system; ROCK, Rho kinase

The first 20% of the full text of this article appears below.

Rho family GTPases have received increasing attention as critical regulators of cell function (1). Initially, they were shown to regulate actin dynamics, thereby modulating development, cell migration, immune responses, and cancer cell invasion and metastasis. More recent studies have shown that they are also involved in cell-cell adhesion and cell cycle progression. RhoA is one of the most widely studied of the 22 mammalian members of the family, and the serine-threonine kinase Rho kinase (ROCK) is a major RhoA effector.

RhoA/ROCK has a number of functions in the kidney. RhoA/ROCK enhances Ca²⁺-dependent vascular smooth muscle contraction, thereby modulating tone (2–4). The potent vasoconstrictor angiotensin II (AngII) activates ROCK in smooth muscle cells. The ROCK inhibitors fasudil and Y-27632 dilate afferent and efferent arterioles and reverse AngII-dependent arteriolar vasoconstriction. At the cellular level, RhoA/ROCK mediates cytoskeletal rearrangement in renal tubule cells, mesangial cells and podocytes and may contribute to epithelial-mesenchymal transdifferentiation, which may be important in the development of renal fibrosis. ROCK inhibitors have renoprotective effects in a number of models of kidney damage (2). They prevent tubulointerstitial fibrosis following unilateral ureteral obstruction, and decrease structural and functional damage in hypertensive models without affecting blood pressure.

When activated, RhoA translocates from the cytoplasm to the cell membrane. RhoA translocation to the . . . [Full Text of this Article]

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article:

Targeting of RhoA/ROCK Signaling Ameliorates Progression of Diabetic Nephropathy Independent of Glucose Control

Vasantha Kolavennu, Lixia Zeng, Hui Peng, Yin Wang, and Farhad R. Danesh
Diabetes 2008 57: 714-723. [Abstract] [Full Text] [PDF]